Skip to main content
. 2022 Jan 21;12:804250. doi: 10.3389/fphar.2021.804250

FIGURE 3.

FIGURE 3

Results from randomized controlled trials: the mortality outcome of sarilumab for COVID-19 (at the edge of sepsis).